Ernexa Therapeutics (ERNAW) Other Accumulated Expenses (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Other Accumulated Expenses data on file, last reported at $274000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses fell 40.43% year-over-year to $274000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $274000.0 (down 40.43% YoY) and the FY2025 annual result came in at $83000.0, down 63.27% from the prior year.
• Other Accumulated Expenses advanced to $274000.0 in Q1 2026, from $83000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $2.6 million in Q3 2022 to a low of $45000.0 in Q1 2022.
• A 5-year average of $554882.4 and a median of $508000.0 in 2023 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses surged 1055.56% — and 2024, when it tumbled 80.52%.
• Tracing ERNAW's Other Accumulated Expenses over 5 years: stood at $590000.0 in 2022, then retreated by 13.9% to $508000.0 in 2023, then slumped by 55.51% to $226000.0 in 2024, then sank by 63.27% to $83000.0 in 2025, then jumped by 230.12% to $274000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $274000.0 (Q1 2026), $83000.0 (Q4 2025), and $63000.0 (Q3 2025), per Business Quant data.